Showing 1 - 10 of 25
Persistent link: https://www.econbiz.de/10009671878
Intelligently allocating research effort and funds requires deciding whether to build on recent advances or on more established knowledge. When recent advances create superior opportunities for invention, their adoption as research inputs in the invention process promotes technological progress....
Persistent link: https://www.econbiz.de/10012460166
Intelligently allocating research effort and funds requires deciding whether to build on recent advances or on more established knowledge. When recent advances create superior opportunities for invention, their adoption as research inputs in the invention process promotes technological progress....
Persistent link: https://www.econbiz.de/10013065176
New ideas no longer fuel economic growth the way they once did. A popular explanation for stagnation is that good ideas are harder to find, rendering slowdown inevitable. We present a simple model of the lifecycle of scientific ideas that points to changes in scientist incentives as the cause of...
Persistent link: https://www.econbiz.de/10012479276
New ideas no longer fuel economic growth the way they once did. A popular explanation for stagnation is that good ideas are harder to find, rendering slowdown inevitable. We present a simple model of the lifecycle of scientific ideas that points to changes in scientist incentives as the cause of...
Persistent link: https://www.econbiz.de/10012841421
Persistent link: https://www.econbiz.de/10012194981
diseases and consumption of treatments to those diseases. This increases the reward for innovation and thus benefits the … innovator. It also increases treatment innovation which benefits all consumers. As individuals do not take these positive … externality for obesity. The lower bound is independent of how much additional innovation is generated. The results show that the …
Persistent link: https://www.econbiz.de/10011051304
The aim of this article is to analyze the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: Minimum Efficacy Standards (MES) and Price Controls (PC). We develop a model of adverse selection where a...
Persistent link: https://www.econbiz.de/10005694983
Persistent link: https://www.econbiz.de/10011411303
Persistent link: https://www.econbiz.de/10009156139